North America’s BEST Small Cap Stock Ideas
On Wednesday, Orsus Xelent Technologies, Inc. (ORS), a designer and manufacturer of mobile phones for the Asian market, announced its full year 2008 results. Revenues for the full year ended December 31, 2008 grew approximately 20% to $107,827,000, compared with $89,923,000 in 2007. Full year net income grew 16.6% to $11,296,000 or $.38 per share, compared with $9,683,000 or $0.33 […]
Read moreOn Friday, Acme United Corporation (ACU – $7.20) announced sales and earnings for the first quarter ended March 31, 2009. As expected, those numbers were soft due to a reduction in orders from many of the Company’s customers as a result of the contracting global economy. However, the Company did manage to remain profitable thanks to a series of cost […]
Read more
In this interview Mr. Walter Johnsen, Exec. Chairman and CEO of Acme United Corp. (ACU – $7.20), gives us an update on the Company’s current condition. He talks about the Company’s dividend policy, the share buyback program and its European segment. Additionally, he gives us some insights on first quarter results. This is an interview worthwhile your time. Click the […]
Read moreDoes the board of Orsus Xelent Technologies Inc. (ORS) read my posts? In my post last week, I wrote that Orsus, a designer and manufacturer of award-winning mobile phones for the Asian market, was my only disappointment so far this year. And what do you know? On Thursday the Company announced a big management shift. Mr. Xin Wang, CEO and […]
Read moreOn Wednesday, James Reindl, Chairman, Director and CEO of TechPrecision Corp. (TPCS) resigned. The press release stated: “Mr. Reindl submitted his resignation and confirmed that despite briefly attending the University of Delaware, he did not receive a degree from the University of Delaware as he had previously represented.” When I visited the TPCS website, Mr. Reindl’s profile was already gone. […]
Read moreLast week, Dr. Strayer, Hemispherx Biopharma’s (NYSE Alternext US: HEB) Medical Director, presented new cytokine and cardiovascular data at the 9th International IACFS/ME conference. This week, Dr. Strayer and Dr Carter, Hemispherx’ CEO, held a conference call in which they gave an update on the Company’s FDA progress and the new released data. In my previous Hemispherx update, which was […]
Read moreEarlier in the week, Boots & Coots International Well Control, Inc. (NYSE Alternext US: WEL) reported very strong fourth quarter and year end results. Revenues for 2008 increased 99% to $209.2 million compared to $105.3 million for the prior year. Net income attributable to common stockholders increased 177% to $21.8 million, or $0.28 per diluted share, compared to $7.9 million, […]
Read moreAlthough no news was announced, Acme United’s (ACU – $7.17) stock price was a real rollercoaster this week. From Monday until Thursday, the stock declined, along with the rest of the market, on small volumes of a few thousand shares. (See 3-month chart on the left) On Friday however, the stock traded 56,500 shares and shot up by more than […]
Read moreRenewable energy Companies come in different shapes and sizes. Some focus on wind or solar power, while others produce energy from geothermal or biomass waste sources. By now, everybody agrees, there’s a limited amount of fossil fuels available on Earth. So gradually, alternative energy will be our only source for energy production. That’s why we’ve seen a real boom of […]
Read moreHemispherx Biopharma (HEB – $0.32) lost more than 38% of its market value yesterady because it announced that its PDUFA date would be extended by three months. A small recap. In July of 2008 the U.S. Food and Drug Administration (FDA) accepted for review the Company’s New Drug Application (NDA) for Ampligen to treat Chronic Fatigue Syndrome (CFS). Hemispherx is […]
Read more